G
Giulia Pasello
Researcher at University of Padua
Publications - 158
Citations - 2672
Giulia Pasello is an academic researcher from University of Padua. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 19, co-authored 113 publications receiving 1597 citations.
Papers
More filters
Journal ArticleDOI
Editorial: Understanding the Interplay Between the Tumor Immune Microenvironment and Genetic Alterations in Thoracic Malignancies
TL;DR: This poster presents a poster presented at the European Society for Medical Oncology Congress (ES congress) in Berlin, Germany, entitled “Oncology and Gastroenterology: Foundations of Clinical Practice and Outcomes of Drug- Assisted Dementia Research.”
Journal ArticleDOI
40P Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): A real-world analysis
G. Pretelli,Alberto Pavan,Alessandro Dal Maso,Maria Vittoria Resi,C. Mulargiu,Alessandra Ferro,Benjamin Benetti,Martina Lorenzi,G. Marinato,Stefano Frega,Giulia Pasello,Pf Conte,Valentina Guarneri,Laura Bonanno +13 more
TL;DR: In this paper , the association of clinical and pathological features with irAEs development was studied by univariate and multivariable logistic regression models, showing that low tumor burden was associated with higher risk of irAE.
Journal ArticleDOI
STYLE (NCT03449173) a phase II Trial of Sunitinib in patients with type B3 Thymoma or Thymic Carcinoma in second and further lines.
Claudia Proto,Sara Manglaviti,G. Lo Russo,Maria Musca,Giulia Galli,Martina Imbimbo,Matteo Perrino,Nadia Cordua,Erica Rulli,Zelmira Ballatore,Alessandro Dal Maso,Antonio Chella,Andrea Sbrana,Arsela Prelaj,Roberto Ferrara,Mario Occhipinti,Maria Elena Brambilla,Alessandro De Toma,Laura Mazzeo,Teresa Beninato,Diego Signorelli,Giacomo Massa,Francesca Greco,Giuseppina Calareso,D. Miliziano,Rosaria Di Mauro,G. Di Mella,A. Lucarelli,Alan A. Del Paggio,F. Galli,Vamsee Torri,Filippo de Braud,Giulia Pasello,Iacopo Petrini,Rossana Berardi,Monica Ganzinelli,Marina Chiara Garassino,Paolo Andrea Zucali +37 more
TL;DR: Sunitinib was administered 50 mg daily for 4 weeks, followed by a 2-week rest period (schedule 4/2), until disease progression or unacceptable toxicity as discussed by the authors .